As filed with the Securities and Exchange Commission on April 25, 2022
Registration No. 333-238123
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO:
FORM S-8 REGISTRATION STATEMENT NO. 333-238123
UNDER
THE SECURITIES ACT OF 1933
KALEIDO BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| | |
Delaware (State or other jurisdiction of incorporation or organization) | | 47-3048279 (I.R.S. Employer Identification No.) |
65 Hayden Avenue
Lexington, MA 02421
(Address of principal executive offices, zip code)
Kaleido Biosciences, Inc. 2019 Stock Option and Incentive Plan
Kaleido Biosciences, Inc. 2019 Employee Stock Purchase Plan
(Full title of the plans)
Daniel L. Menichella
Chief Executive Officer and President
Kaleido Biosciences, Inc.
65 Hayden Avenue
Lexington, MA 02421
(Name and address of agent for service)
(617) 674-9000
(Telephone number, including area code, of agent for service)
with copies to:
Kingsley L. Taft
Laurie A. Burlingame
Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | |
Large accelerated filer | | ☐ | | Accelerated filer | | ☐ |
| | | |
Non-accelerated filer | | ☒ | | Smaller reporting company | | ☒ |
| | | |
| | | | Emerging growth company | | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒